Market Currents
Novartis (NVS) obtains global rights to an experimental heart drug it hopes will rival...
-
Thursday, February 12, 2009, 9:31 AM ETNovartis (NVS) obtains global rights to an experimental heart drug it hopes will rival blockbuster Plavix (BMY, SNY). It will cost Novartis $75M upfront, up to $500M more based on certain milestones and royalty payments. An announcement is expected today.
Other date
Latest Articles
